Compare ALEMBIC PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NATCO PHARMA ALEMBIC PHARMA/
NATCO PHARMA
 
P/E (TTM) x 15.6 15.5 100.4% View Chart
P/BV x 3.6 3.1 117.6% View Chart
Dividend Yield % 1.1 1.5 72.7%  

Financials

 ALEMBIC PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
NATCO PHARMA
Mar-18
ALEMBIC PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs6641,080 61.5%   
Low Rs412671 61.4%   
Sales per share (Unadj.) Rs208.7592.1 35.3%  
Earnings per share (Unadj.) Rs31.0188.4 16.5%  
Cash flow per share (Unadj.) Rs37.1206.3 18.0%  
Dividends per share (Unadj.) Rs5.508.25 66.7%  
Dividend yield (eoy) %1.00.9 108.5%  
Book value per share (Unadj.) Rs144.2833.6 17.3%  
Shares outstanding (eoy) m188.5236.90 510.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.61.5 174.4%   
Avg P/E ratio x17.44.6 373.6%  
P/CF ratio (eoy) x14.54.2 341.7%  
Price / Book Value ratio x3.71.1 355.3%  
Dividend payout %17.74.4 405.2%   
Avg Mkt Cap Rs m101,46132,311 314.0%   
No. of employees `000NA4.8 0.0%   
Total wages/salary Rs m7,4673,256 229.3%   
Avg. sales/employee Rs ThNM4,522.5-  
Avg. wages/employee Rs ThNM674.0-  
Avg. net profit/employee Rs ThNM1,439.0-  
INCOME DATA
Net Sales Rs m39,34721,848 180.1%  
Other income Rs m94404 23.2%   
Total revenues Rs m39,44122,252 177.2%   
Gross profit Rs m8,7369,284 94.1%  
Depreciation Rs m1,152662 174.1%   
Interest Rs m184154 119.5%   
Profit before tax Rs m7,4938,872 84.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5681,920 81.6%   
Profit after tax Rs m5,8446,952 84.1%  
Gross profit margin %22.242.5 52.2%  
Effective tax rate %20.921.6 96.7%   
Net profit margin %14.931.8 46.7%  
BALANCE SHEET DATA
Current assets Rs m19,57721,307 91.9%   
Current liabilities Rs m14,8965,920 251.6%   
Net working cap to sales %11.970.4 16.9%  
Current ratio x1.33.6 36.5%  
Inventory Days Days9073 122.5%  
Debtors Days Days45107 42.6%  
Net fixed assets Rs m27,09714,986 180.8%   
Share capital Rs m377369 102.2%   
"Free" reserves Rs m26,81130,353 88.3%   
Net worth Rs m27,18830,760 88.4%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77837,151 128.6%  
Interest coverage x41.758.6 71.2%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.6 140.0%   
Return on assets %12.619.1 66.0%  
Return on equity %21.522.6 95.1%  
Return on capital %23.629.3 80.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45310,322 188.5%   
Fx outflow Rs m6,0652,978 203.6%   
Net fx Rs m13,3887,343 182.3%   
CASH FLOW
From Operations Rs m8,1204,636 175.1%  
From Investments Rs m-7,556-11,155 67.7%  
From Financial Activity Rs m5906,509 9.1%  
Net Cashflow Rs m1,153-18 -6,407.2%  

Share Holding

Indian Promoters % 74.1 52.0 142.4%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 2.9 7.8 37.0%  
FIIs % 9.1 16.6 54.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 26.0 53.5%  
Shareholders   49,328 25,395 194.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   IPCA LABS  NOVARTIS  PLETHICO PHARMA  PROCTER & GAMBLE HEALTH  TORRENT PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS